Ironwood Pharmaceuticals Inc
IRWD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001446847
In the last 90 days, Ironwood Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 212 institutions reported holding it in 13F filings for Q2 2026, worth $675.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ironwood Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $578.1K in total
- Insiders trading
- 1
- Net value
- −$578.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ironwood Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Denner Alexander J | Director | 327,549 | Sep 17, 2026 | 4 |
| Silber Jeffrey | SVP, CMO, Head-Res&Drug | 137,036 | Jul 22, 2026 | 1 |
| Silver Ronald | PFO & PAO | 313,680 | Jul 9, 2026 | 5 |
| Currie Mark G | Director | 676,900 | Jun 17, 2026 | 1 |
| McHugh Julie | Director | 250,749 | Jun 17, 2026 | 1 |
| Shepard Jay | Director | 235,036 | Jun 17, 2026 | 1 |
| Kessler Marla L | Director | 229,364 | Jun 17, 2026 | 1 |
| Duane Jon R | Director | 253,820 | Jun 17, 2026 | 1 |
| Moukheibir Catherine | Director | 181,425 | Jun 17, 2026 | 1 |
| MCCOURT Thomas A | Chief Executive Officer | 1,898,838 | Mar 12, 2026 | 2 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 658,037 | Mar 12, 2026 | 2 |
| John Minardo | Chief Legal Officer | 500,498 | Mar 12, 2026 | 2 |
| Martini Gregory S. | Chief Financial Officer | 297,213 | Mar 12, 2026 | 2 |
| Gaskins Tammi L | Chief Commercial Officer | 350,350 | Mar 12, 2026 | 3 |
| Sarissa Capital Management LP | 10% Owner | 251,858 | Dec 17, 2025 | 1 |
| Dreyfus Andrew | Director | 228,313 | Jun 12, 2025 | 0 |
| Emany Sravan Kumar | SVP, COO and CFO | 309,572 | Nov 20, 2024 | 0 |
| Davis Andrew | SVP, Chief Business Officer | 284,685 | Nov 20, 2024 | 0 |
| Rickard Jason | SVP, Chief Operating Officer | 376,316 | Mar 10, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 29, 2023 (view filing) | Mar 27 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −46.1K | $10.67 | −$492.2K | −5.2%842.1K after | |
| Mar 7, 2023 (view filing) | Mar 3 | 4 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −33.8K | $11.22 | −$378.7K | −5.0%647.6K after | |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −5.98K | $11.36 | −$67.9K | −5.7%98.5K after | 2 lots |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −34.2K | $11.36 | −$388.2K | −9.3%332.6K after | 4 lots |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −61.2K | $11.36 | −$695.5K | −8.2%681.4K after | 4 lots |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −19.3K | $11.36 | −$219.5K | −6.9%261.6K after | 4 lots |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −6.70K | $11.36 | −$76.1K | −4.8%133.7K after | 2 lots |
| Mar 1, 2023 (view filing) | Feb 27-28 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −3.57K | $11.36 | −$40.6K | −2.3%151.4K after | 2 lots |
| Jan 9, 2023 (view filing) | Jan 5 | 4 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −111.0K | $12.07 | −$1.34M | −13.5%712.4K after | |
| Dec 16, 2022 (view filing) | Dec 14 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −27.0K | $12.39 | −$334.5K | −7.2%348.7K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −682 | $11.56 | −$7.88K | −0.6%104.5K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Emany Sravan KumarSVP, Chief Financial Officer | SSaleClass A Common Stock | −6.58K | $11.56 | −$76.0K | −7.7%78.4K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −3.33K | $11.56 | −$38.6K | −2.1%154.2K after | |
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −18.9K | $10.41 | −$196.7K | −2.6%712.4K after | |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −26.4K | $10.65 | −$281.6K | −3.5%731.3K after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −2.01K | $11.77 | −$23.7K | −1.9%105.2K after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −994 | $11.77 | −$11.7K | −0.3%375.7K after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −7.33K | $11.77 | −$86.3K | −5.0%140.4K after | |
| Aug 15, 2022 (view filing) | Aug 11 | 4 days | Currie Mark GDirector | SSaleClass A Common Stock | −70.0K | $11.78 | −$824.6K | −11.8%521.8K after | |
| Aug 10, 2022 (view filing) | Aug 8-9 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −47.5K | $11.68 | −$554.4K | −11.2%376.7K after | 3 lots |
| Aug 3, 2022 (view filing) | Aug 1 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −23.2K | $11.35 | −$263.6K | −3.0%757.8K after | |
| Jul 5, 2022 (view filing) | Jun 30 | 5 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −20.0K | $11.58 | −$231.1K | −2.5%778.9K after | |
| Jun 16, 2022 (view filing) | Jun 14 | 2 days | Kessler Marla LDirector | SSaleClass A Common Stock | −7.61K | $11.65 | −$88.7K | −8.3%84.1K after | |
| Jun 9, 2022 (view filing) | Jun 7 | 2 days | Currie Mark GDirector | SSaleClass A Common Stock | −190.4K | $12.01 | −$2.29M | −24.3%591.8K after | |
| May 25, 2022 (view filing) | May 23 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −36.3K | $11.50 | −$417.5K | −4.3%798.9K after | 3 lots |
| May 25, 2022 (view filing) | May 23 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −120 | $11.50 | −$1.38K | −0.1%105.1K after | |
| May 25, 2022 (view filing) | May 23 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −10.6K | $11.50 | −$121.7K | −3.8%266.2K after | 2 lots |
| May 25, 2022 (view filing) | May 23 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −13.5K | $11.50 | −$155.7K | −3.2%404.1K after | 2 lots |
| Mar 25, 2022 (view filing) | Mar 24 | 1 day | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −3.03K | $12.75 | −$38.6K | −2.8%105.2K after | |
| Mar 16, 2022 (view filing) | Mar 14 | 2 days | McHugh JulieDirector | SSaleClass A Common Stock | −20.0K | $11.67 | −$233.4K | −14.5%118.4K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −2.24K | $10.77 | −$24.1K | −3.5%61.2K after | 3 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −48.4K | $10.77 | −$521.5K | −7.6%586.3K after | 4 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −17.6K | $10.77 | −$189.6K | −8.3%195.4K after | 5 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −29.0K | $10.77 | −$311.9K | −8.1%327.1K after | 5 lots |
| Dec 23, 2021 (view filing) | Dec 22 | 1 day | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −46.3K | $11.41 | −$528.6K | −7.5%574.5K after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −27.0K | $11.28 | −$304.6K | −7.8%319.9K after | |
| Dec 16, 2021 (view filing) | Dec 14 | 2 days | McHugh JulieDirector | SSale | −10.0K | $11.02 | −$110.2K | −6.7%138.4K after | |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −52.6K | $11.58 | −$609.6K | −7.8%618.5K after | |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −17.2K | $11.58 | −$199.1K | −4.8%344.7K after | 2 lots |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −13.8K | $11.58 | −$159.5K | −7.0%183.7K after | |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −1.46K | $11.58 | −$16.9K | −2.3%61.2K after | 2 lots |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −567 | $13.48 | −$7.64K | −0.9%62.7K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Rickard JasonSVP, Chief Operating Officer | SSaleClass A Common Stock | −680 | $13.48 | −$9.17K | −0.2%361.9K after |